Illuminating Uveitis; Lux Seeks Luveniq Approval in U.S., Europe

With simultaneous filings for uveitis drug Luveniq in the U.S. and Europe, Lux Biosciences Inc. has done what few small, private biotechs have managed in today's tough economy: get a drug to market without the help of public funding or a big pharma partner. (BioWorld Today)